The 15th International Symposium on Anti-Angiogenic Therapy:
Recent Advances and Future Directions in Basic and Clinical Cancer Research

January 31–February 2, 2013

www.antiangio2013.com
For Information and Poster Submission Form
Program Overview

Angiogenesis is an essential process in the growth of neoplasms and progression to metastasis. The angiogenic pathway is orchestrated by a range of pro- and anti-angiogenic factors that ultimately lead to the development of a neovascular blood supply to the tumor mass. Vascular endothelial growth factor (VEGF), which stimulates proliferation and migration of endothelial cells, plays a pivotal role in this process. For these reasons, the inhibition of VEGF and its receptor signaling system are attractive targets for therapeutic intervention. Indeed, the approval in 2004 of a neutralizing monoclonal antibody directed against VEGF — the first anti-angiogenic systemic drug to treat cancer patients — validated the notion introduced decades earlier that inhibition of tumor angiogenesis may be a valid approach to control tumor growth. This success has driven the search for new anti-angiogenic agents. For example, small-molecule multikinase inhibitors that target VEGF receptors have recently demonstrated efficacy in multiple tumor types. A number of other anti-angiogenic agents targeting an increasing variety of molecular tumor features are in clinical development. More recently, studies of powerful new genetic and cell biological approaches have provided unprecedented insights into how various molecular are pivotal to tumor growth and survival. As a consequence, a number of new angiogenic molecules, such as neuropilins, Tie-2, and Notch ligand delta-like 4, have emerged as promising targets.

Since its inception over 40 years ago, investigators in the field of tumor angiogenesis research have made significant progress. Advancements in therapeutics have altered cancer treatment paradigms, and the next decade promises to be an exciting and productive time. This annual state-of-the-art symposium is designed to continue the dialogue and interaction between research and clinical investigators by reviewing the current scientific understanding of vascular biology and angiogenesis. In addition, this symposium provides a forum for presenting the most current preclinical and clinical data on emerging anti-angiogenic agents and regimens. Strategies that inhibit angiogenesis in colorectal, breast, lung, esophageal, gastric, genitourinary, neuroendocrine, central nervous system, hepatocellular and gynecologic malignancies will be discussed. In addition, biomarkers and resistance pathways will be addressed and controversies in the field will be highlighted.

Educational Objectives

After attending the symposium, participants should be able to

• Define angiogenesis and its relevance to the treatment of cancer (Knowledge);

• Outline the rationale for the development of anti-angiogenic agents, and explain why angiogenic signaling pathways are targets for inhibition (Knowledge);

• Summarize data from clinical trials that support the use of currently available anti-angiogenic agents as monotherapy or in combination with other therapeutic modalities, which will ultimately assist the healthcare provider to make appropriate clinical decisions (Knowledge, Competence, Performance, Patient Outcomes);

Target Audience

This symposium is designed for medical, surgical, and radiation oncologists, pharmacists, other providers of cancer care (PAs, RNs, etc.), and research scientists who have an interest in the biology, diagnosis, and treatment of cancer, as well as those who diagnose and treat patients with nonmalignant vascular diseases, such as arthritis and retinal neovascularization. As new and emerging data on anti-angiogenic therapy is presented at this symposium every year, it is necessary for this audience to be made aware of these findings so they can be utilized in their clinical practice.

Educational Methods

Lectures – Panel Discussions – Question and Answer – Poster Session

Evaluation

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

Accreditation/Credit Designation

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 14.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME Certificates and Attendance Verification Certificates

Certificates awarding AMA PRA Category 1 Credit™ or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a CME Verification Form.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

Planning Committee

Lee M. Ellis, MD
Professor of Surgery and Cancer Biology
William C. Lieddke, Jr., Chair in Cancer Research
The University of Texas MD Anderson Cancer Center
Houston, Texas

Robert S. Kerbel, PhD
Canada Research Chair in Tumor Biology, Angiogenesis and Anti-Angiogenic Therapy
University of Toronto
Professor, Molecular and Cellular Biology Research
Sunnybrook Health Sciences Centre/Odette Cancer Centre
Toronto, Ontario, Canada

George W. Sledge, Jr., MD
Ballve-Lantero Professor of Oncology
Co-Director, Breast Cancer Program
Indiana University Melvin and Ben Simon Cancer Center
Indianapolis, Indiana

Helen X. Chen, MD
Senior Investigator in Cancer Therapy Evaluation Program
National Cancer Institute
Rockville, Maryland

Axel Grotbey, MD
Professor of Oncology
Division of Medical Oncology
Mayo Clinic Division of Medical Oncology
Rochester, Minnesota

Gloria Buckman, MD
Professor and Director
National Heart, Lung, and Blood Institute
Bethesda, Maryland

The symposium will feature a poster session where academics and investigators from the industry present angiogenesis-related data from both clinical trials and laboratory research. Trainees are especially encouraged to present their research. Accepted posters will be displayed with ample time for viewing and discussions.

All symposium participants, including members of industry, are encouraged to present research data as part of the poster session.

The deadline for submitting poster applications is Friday, December 14, 2012.

Please check the website for more information and the submission form at www.antiangio2013.com.
### Session I: Basic Biology and Preclinical Data

**Moderator:** Lee M. Ellis, MD; Robert S. Kerbel, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00–8:30</td>
<td>Opening Remarks/Overview&lt;br&gt;Lee M. Ellis, MD</td>
</tr>
<tr>
<td>8:30–8:55</td>
<td>Combinatorial Targeting of Endothelial Growth Factors and Receptors&lt;br&gt;Kari Alitalo, MD, PhD</td>
</tr>
<tr>
<td>8:55–9:20</td>
<td>Tumor Hypoxia: Is Targeting HIF a Viable Approach?&lt;br&gt;M. Celeste Simon, PhD</td>
</tr>
<tr>
<td>9:20–9:45</td>
<td>Metronomic Chemotherapy with Anti-Angiogenic Drugs: An Update&lt;br&gt;Robert S. Kerbel, PhD</td>
</tr>
<tr>
<td>9:45–10:10</td>
<td>Resistance to VEGF-Targeted Therapies&lt;br&gt;TBD</td>
</tr>
<tr>
<td>10:10–10:30</td>
<td>Break</td>
</tr>
<tr>
<td>10:30–10:55</td>
<td>Anti-Angiogenic Agents Stimulate Breast Cancer Stem Cells via Generation of Tumor Hypoxia&lt;br&gt;Max S. Wicha, MD</td>
</tr>
<tr>
<td>10:55–11:10</td>
<td>Abstract #1</td>
</tr>
<tr>
<td>11:10–11:35</td>
<td>The Role of SDF-1/CXCR4 Signaling in Angiogenesis&lt;br&gt;Martin Brown, DPhil</td>
</tr>
<tr>
<td>11:35–Noon</td>
<td>Oscillation of Immune Cells in Response to Anti-Angiogenic Therapy&lt;br&gt;Gabriele Bergers, PhD</td>
</tr>
</tbody>
</table>

### Session II: Biomarkers and Imaging

**Moderator:** Robert S. Kerbel, PhD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>1:00–1:25</td>
<td>Predictive Biomarkers: VEGF Amplifications and Host Polymorphisms&lt;br&gt;Bryan P. Schneider, MD</td>
</tr>
<tr>
<td>1:25–1:50</td>
<td>Predictive Biomarkers: Imaging and Circulating VEGF&lt;br&gt;Gordon Jayson, MD, PhD</td>
</tr>
<tr>
<td>1:50–2:05</td>
<td>Abstract #2</td>
</tr>
<tr>
<td>2:05–2:30</td>
<td>Standardizing Imaging Criteria to Assess the Effect of Anti VEGF Therapy in Brain Tumors&lt;br&gt;Bradley J. Erickson, MD, PhD</td>
</tr>
<tr>
<td>2:30–2:55</td>
<td>The FDA Pre-IDE Process: Lessons Learned for Integral Markers&lt;br&gt;J. Milburn Jessup, MD</td>
</tr>
<tr>
<td>2:55–3:15</td>
<td>Break</td>
</tr>
<tr>
<td>3:15–3:45</td>
<td>Panel Discussion: Implementation of Biomarkers&lt;br&gt;Moderator: Lee M. Ellis, MD&lt;br&gt;Panelists: S. Gail Eckhardt, MD; Bradley J. Erickson, MD, PhD; Axel Grothey, MD; Gordon Jayson, MD, PhD; J. Milburn Jessup, MD; Bryan P. Schneider, MD</td>
</tr>
</tbody>
</table>

### Session III: Controversies and New Horizons

**Moderators:** Axel Grothey, MD; George W. Sledge, Jr., MD

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00–8:05</td>
<td>Introduction&lt;br&gt;George W. Sledge, Jr., MD</td>
</tr>
<tr>
<td>8:05–8:25</td>
<td>Is RECIST Still Relevant in the Era of VEGF Inhibition Through Multiples Lines of Therapy?&lt;br&gt;Implications for Clinical Trial Design in All Malignancies&lt;br&gt;Axel Grothey, MD</td>
</tr>
<tr>
<td>8:25–8:50</td>
<td>Patient Derived Xenograft Models: Are They Appropriate For Anti-Angiogenic and Microenvironment Therapies?&lt;br&gt;S. Gail Eckhardt, MD</td>
</tr>
<tr>
<td>8:50–9:15</td>
<td>From the Laboratory to the Labrador: Spontaneous Canine Cancer as a Model for Anti-Angiogenic Drug Development&lt;br&gt;Douglas H. Thamm, VMC, DACVIM</td>
</tr>
<tr>
<td>9:15–9:40</td>
<td>Promise and Pitfalls of Anti-Angiogenic Therapy in the Adjuvant Setting&lt;br&gt;Daniel F. Hayes, MD</td>
</tr>
</tbody>
</table>
Session IV: Early Drug Development
Moderators: Helen X. Chen, MD; George W. Sledge, Jr., MD

9:40–10:00 Break

10:00–10:15 Early Drug – Phase I
Michael S. Gordon, MD

10:15–10:30 Early Drug – Phase I
Lee S. Rosen, MD

10:30–10:45 Abstract #3

10:45–11:00 A Phase I Clinical Trial of VX15/2503, A Novel Humanized IgG4 Anti-SEMA4D Antibody, In Patients With Advanced Solid Tumors
Amita Patnaik, MD

11:00 –11:25 The Role of CTEP in the Development of Angiogenesis Inhibitors
Helen X. Chen, MD

11:30–12:30 p.m. Lunch

Session V: Clinical Trial Results
Moderator: Helen X. Chen, MD; Michael S. Gordon, MD

12:30-12:55 Anti-Angiogenic Therapy for the Treatment of Hepatocellular Carcinoma
Ghassan K. Abou-Alfa, MD

12:55–1:20 Anti-Angiogenic Therapy for the Treatment of Sarcoma
Gary K. Schwartz, MD

1:20–1:45 Anti-Angiogenic Therapy for the Treatment of Ovarian Cancer
Gordon Jayson, MD, PhD

1:45–2:05 Break

2:05–2:30 Anti-Angiogenic Therapy for the Treatment of Colorectal Cancer
Charles D. Blanke, MD

2:30–2:45 Abstract #4

2:45–3:10 Anti-Angiogenic Therapy for the Treatment of Renal Cell Carcinoma
Eric Jonasch, MD

3:10–3:25 Vascular Disrupting Agents
Gordon Rustin, MD

3:35 Adjourn

Saturday, February 2, 2013

7:30–8:00 a.m. Registration/Continental Breakfast

Session V: Clinical Trial Results
Moderator: Axel Grothey, MD

8:00–8:05 Introduction
Axel Grothey, MD

8:05–8:30 Clinical Overview and Perspectives on Anti-Angiogenic Therapy in CNS Tumors
Patrick Y. Wen, MD

8:30–8:55 Antio-Angiogenic Therapy for the Treatment of Neuroendocrine Tumors
James C. Yao, MD

8:55–9:10 Abstract #5

9:10–9:35 Anti-Angiogenic Therapy for the Treatment of Lung Cancer
Corey J. Langer, MD

9:35–10:00 Anti-Angiogenic Therapy for the Treatment of Breast Cancer
George W. Sledge, Jr., MD

10:00 Closing Remarks

10:15 Adjourn
Registration Information

On-site registration will be open from 3:00-7:00 p.m. on Wednesday, January 30, 2013, and at 7:30 a.m. on Thursday, January 31. The conference will begin at 8:00 a.m. on Thursday, January 31, and adjourn at 10:15 a.m. on Saturday, February 2. Advance registration is encouraged as space and materials are limited. Please see registration form for applicable fees.

The deadline for advance registration is January 16, 2013.

There are three ways to register:

- Mail to: CME/Conference Management–Unit 1381, The University of Texas MD Anderson Cancer Center, P.O. Box 301439, Houston, TX 77230-1439
- Fax to: 713-794-1724
- On-line at www.mdanderson.org/conferences

We accept the following forms of payment:

- Check (payable through U.S. banks only)
- Money Order
- Credit Cards (MasterCard, VISA, and American Express)
- Cash (on-site registration only)

A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee.

The full conference registration fee includes the tuition, breaks, lunch, and poster reception.

Refund/Cancellation Policy:

The registration fee, minus a $50 administrative handling fee, is refundable if a written request is received on or before January 16, 2013. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e-mail, or the contact numbers as given on the registration form.

In case of activity cancellation, liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee. The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

For additional information, contact CME/Conference Management at 713-792-2223 or toll free at 866-849-5866.
Special Assistance
Contact the Department of CME/Conference Management at 713-792-2223 or toll free at 866-849-5866 if you have any special dietary or ADA accommodation needs.

Accommodations
- A block of rooms has been reserved for conference attendees at the Hyatt Regency La Jolla, 3777 La Jolla Village Drive, San Diego, California.
- Early hotel reservation is suggested.
- The hotel reservations number is 858-552-1234.
- When you make reservations be sure to mention the MD Anderson 15th International Symposium on Anti-Angiogenic Agents to be assured of receiving the special meeting rate of $215.00 single or double occupancy. Please add 12.5% California state and local taxes. Reservations and deposits received after December 28, 2012 will be confirmed if space is available and at current hotel published guest room rates.

Ground Transportation
The hotel is approximately 20 miles from the San Diego International Airport. Taxi rates are approximately $45 one way.